{
  "date": "2026-10-24",
  "status": "Exploratory extension written AFTER seeing initial broad-study results. Must never be described as preselected or untouched validation.",
  "hypothesis": "Monthly inverse-variance control preserved much of Nasdaq return while reducing drawdown in the initial run. Test whether it can support a 60% normal Nasdaq budget, and whether mild dividend mean reversion adds a separate benefit. Do not fine-tune the volatility formula or RSI/deviation thresholds.",
  "scope": "Original40/20/10/30 and50/20/10/20 plus60/20/10/10 in Nasdaq/dividend/gold/bond order. Each: fixed, Nasdaq invvar21 with dividend hold/invvar21/deviation10/RSI. Include only newly distinct specifications; no further grid search. Report complete outcomes and stress tests, not only winners.",
  "controls": "Static matched average actual exposure, quarterly rebalance. It is a hindsight exposure diagnostic, not an ex-ante recommendation. Costs0.1/0.3/0.5%, monthly execution delay7 calendar days, NAV-generated signals delayed7days, reset at2019 actualETF start. Show post2020 and both market/NAV, including higher-Nasdaq fixed benchmark even if risk is excessive.",
  "no_guarantee": "The 60% normal Nasdaq budget can exceed the user's15%/20% historical-risk preference under stress. Test rather than assume safety. No future max-drawdown guarantee. No leverage, targets unchanged between checks except quarterly rebalancing."
}